Tomoo Nakata 1 2, Satoshi Ikeda 1, Seiji Koga 1, Tsuyoshi Yonekura 1, Akira Tsuneto 1, Yoshiyuki Doi 1, Satoki Fukae 1, Takako Minami 1, Hiroaki Kawano 1, Koji Maemura 1
Main idea: Benzbromarone has increased adiponectin besides reducing uric acid levels, and thus, this might confer more benefits on endothelial function than febuxostat in patients with hyperuricemia
Uric acid is generated with reactive oxygen species via xanthine oxidase (XO), and hyperuricemia has been associated with vascular dysfunction. This study determined and compared the effects of benzbromarone (urate transporter 1 inhibitor) and febuxostat (Xo inhibitor) on endothelial function. The effects of urate-lowering medicines on vascular function have not been fully elucidated, they say. The study was a randomized, cross-over, open-label study. Our findings show that levels of uric acid significantly decreased, whereas those of HMW adiponectin and the RHI have significantly increased after treatment with benzbromarone. In patients administered with febuxostat, Uric Acid levels tended to decrease and RHI significantly decreased. Neither of the two agents altered ADMA levels.